Rebirth of the God-level Xueba

"This is sildenafil."

"I can't see anything."

"It's really interesting that you said this medicine. It's a small thing that can sell for hundreds of millions of dollars."

A group of laymen surrounded the raw material medicine of sildenafil, expressing emotion.

The sildenafil used for clinical trials does not need to be dyed, but pure white starch and some raw materials are used to condense it into small tablets, which have neither taste nor appearance.

If medical experts are discussing with each other, they can probably say something new about acetylcholine.

However, in the eyes of a group of bankers who deal with money all day, this thing looks so fake.

"Professor Yang is here." Someone saw Yang Rui and immediately called out.

Several bank cadres of Zhongnong Construction Engineering immediately straightened up and smiled kindly.

"Professor Yang is here."

"Congratulations on making the medicine."

"I wish you a successful experiment."

Several cadres seemed to be paying New Year's greetings, hand in hand and saying auspicious words.

What everyone said was true.

Although Pfizer finally sold sildenafil to Yang Rui, it paid a high price, an additional US$180 million! Moreover, it is still a milestone - if a finished antihypertensive drug is made, no matter whether it is launched in any country in the world, an additional 200 million US dollars will be added, and then, if it is launched in Europe or the United States, an additional 200 million US dollars will be added .

It is equivalent to saying that if the anti-stress drug made of sildenafil is sold in the United States, no matter how much it sells, Pfizer will take 580 million US dollars.

This is not over yet. If it sells well, that is, if the annual sales exceed 100 million U.S. dollars, Pfizer will take 18%—18% of the sales, and convert it into profits, which is 20 to 30 percent. It is still a milestone... If the sales exceed 1 billion US dollars and become a blockbuster, Pfizer will take 25% of the sales revenue.

Simply insane.

To be honest, such an offer means that Pfizer can offer it.

That is, Yang Rui can give it.

Changing to a pharmaceutical company like Zeneca may not necessarily have such courage.

The highest state of the milestone is 580 million US dollars, plus 25% of the sales. The latter is achieved when the sales exceed 1 billion US dollars, which is equivalent to 250 million US dollars a year. The patent period of 15 consecutive years is 3.8 billion. superior.

A patented compound that has just passed the first phase of clinical trials has sold 180 million US dollars off the line and 3.8 billion on the line. It is also one of the highest prices in the pharmaceutical industry that has not come in 90 years.

This is the result of Yang Rui's hard work—of course, in order to focus the milestone on one point of anti-stress medicine, Yang Rui also put some water in it.

Still, the price is high enough for a compound.

Even if it is a finished drug, it is enough to sell hundreds of millions of dollars.

Double-digit deals are uncommon.

Even foreign companies such as Zeneca seldom offer such a big milestone deal. For example, Yang Rui’s deferiprone, at the end of the milestone, is only the starting price of sildenafil, and he still sells 7 active compounds together.

This is the case with large pharmaceutical companies. On the one hand, they squeeze small biotechnology companies, and on the other hand, they fill the market space with strong capital.

If it weren't for the background of the Chinese market, Yang Rui would not be able to pull out a high price.

Of course, the current high price is not a problem for Yang Rui.

All the milestones are for the antihypertensive effect of sildenafil, not for other indications. Although Pfizer is not very willing to sign the contract like this, it is also holding its nose and accepting it.

In fact, most medicines have additional effects. In professional terms, they can target other indications.

Simply put, the side effects of drugs can be used as new indications for drugs.

Such as the most common diarrhea.

Diarrhea is a side effect of many drugs, but if the effect of diarrhea is good, the drugs that are prone to diarrhea can naturally be used as laxatives.

On the contrary, some medicines can cause constipation in patients, so if the effect of constipation is good, can it be made into an antidiarrheal medicine?

For another example, among the common side effects of antihypertensive drugs, there is often tachycardia. For many patients, especially elderly patients, this is not good, but for patients with bradycardia, this is a good thing, so, da da, a drug that can treat bradycardia Fresh out of the oven, with a side effect of lowering blood pressure…

In the same way, some drugs have the side effect of lowering the heart rate, so it can work again in patients with tachycardia.

It can be seen that the panacea is impossible to appear in the era of chemical drugs.

Your medicine cannot both cause diarrhea and stop it, likewise it cannot both lower and raise blood pressure, raise and lower heart rate.

Aspirin is already a magic medicine. It can reduce inflammation, relieve pain, treat colds, inhibit platelets, and prevent strokes. Even so, try feeding aspirin to nobles with hemophilia, and they will smash eight handles for it The scepter, let you pay for the gems above.

For pharmaceutical companies, developing a new indication for a drug is a matter of increasing profits.

Because there is no need to do animal experiments and the first and second clinical phases, as long as its efficacy is proved in the third clinical phase, the cost is relatively low.

However, not every drug is a miracle drug of aspirin. In fact, there are not many drugs that can perform well in the development of new indications, and the sales volume is naturally not easy to increase.

On the other hand, the patent term is not endless. The general patent term of a drug is slightly more than 15 years, and the extra part is usually the additional patent term applied for, but it is also in single digits. In other words, it can monopolize Patent medicines that have been on the market for 25 years are rare.

To develop new indications, what is added is a "slightly more" part, which is equivalent to using follow-up costs such as clinical phase III and phase IV in exchange for a single-digit increase in the patent term. Cost-effective or not, not sure.

Most of the time, the development of new indications is not so much a new usage of the drug as a trick of the pharmaceutical company to extend the patent period.

If you think about it more deeply, the new indication of the drug is equal to the side effect. The better the effect on the new indication, the stronger and clearer the side effect is. For a drug, this is a double-edged sword. Pharmaceutical companies would rather have a drug with minimal side effects and no new indications, than a drug with strong side effects and multiple new indications.

Using the analogy of making a movie, the original indication of a drug is equivalent to the box office of the theater, and it is the main way for the company to make money. The new indications are equivalent to the sales revenue of DVDs, Blu-ray discs, peripherals, etc. Some companies are better at these and make money through this, but they are not mainstream and unstable after all.

Under Yang Rui's insistence, Pfizer gave up part of the later profits and focused on the main income part, which also has its own routine.

In terms of profit and loss alone, they have already made money from the day Yang Rui's 180 million US dollars arrived in the account, and the rest are pure profits.

Of course, it is impossible for Yang Rui to come up with 180 million US dollars in one go.

Through the coordination of several big bosses, Yang Rui borrowed the money from the four major banks of Gongnong Zhongjian in the name of Huarui Company. Each family bears tens of millions of quotas, and everyone's face is pale with horror.

Not only that, Yang Rui also has no money to give the milestone of 200 million US dollars plus 200 million US dollars in the later stage-the milestone that must be given when it goes public, regardless of the sales volume, can produce a drug with an annual sales of 200 to 300 million US dollars in the early stage. It is also rare.

Naturally, Pfizer couldn't let the well-designed milestones go to waste, not to mention that Yang Rui didn't have that much money, even if he had it. The development cycle of a drug can be measured in ten years. During this period, what should he do if he runs out of money?

Therefore, Gongnong Zhongjian had to give Yang Rui a guarantee.

With a total amount of US$580 million, in the eyes of the bank, they took more risks than Yang Rui.

This can be seen from the importance they attach to the Clinical Trial Center of Hedong University. The four major banks have dispatched special personnel from the headquarters to take charge of this matter. cadres came to inspect.

There is no way, although the country has gradually gained some money in the past two years, and can afford tens of millions of dollars at every turn, but the expenditure of hundreds of millions of dollars is still very powerful. What can be compared with it is the construction of some basic projects, such as railways, roads, bridges, telecommunications, power grids, hydropower stations, and so on.

Compared with those projects that can be seen and touched, and can be charged after completion, the research and development of sildenafil is really not worry-free.

Yang Rui wasn't going to let them worry about it either, and the vaccinations went on and on three times:

"No one dares to say 100% in scientific research. We will definitely do our best, and everyone should keep an open mind."

"Although our clinical trial center has just been built and is relatively inexperienced, as long as we seize the opportunity, we will soon become a mature team."

"Sildenafil's animal experiments and the first phase of clinical trials are very good safety experiments. In the second phase, it is a completely unfamiliar blank field, and foreigners have never done it. We are creating history every step of the way. Now, please witness with me."

Several senior cadres of the bank are going crazy.

In the past, when I went to inspect loan companies, even if they didn’t finish their last meal, they would pat their chests and spit out some fresh abalone to prove it.

Is this the way you do scientific research?

Can you have some confidence?

In the past, lending companies made us come with confidence.

Witness history?

Who wants to witness history?

Hundreds of millions of dollars!

Enough to see how many trips to Paris!

Paris……

milan...

long legs...

roasted elbow...

bikini...

Blonde……

A group of bank officials held their chests together and looked at the large ward behind the single-sided glass, feeling that their blood pressure could no longer be controlled.

The genius remembers the address of this site in one second:. Vertex Novels mobile version reading website: